en.Wedoany.com Reported - Evonik has reached an agreement with the ProChem Group to sell its pharmaceutical raw material production assets in Germany's Hanau and transfer the GMP-compliant production facilities to this contract manufacturer. The transaction is expected to close on June 19, 2026.

As part of its strategy to streamline asset allocation in its Health Care business, Evonik is focusing investments and growth on advanced oral and injectable drug delivery technologies, precision biological solutions, particularly lipids for mRNA and gene delivery, and advanced cell culture raw materials. Evonik ceased keto acid production at the Hanau site at the end of 2025 and consolidated the entire pharmaceutical-grade keto acid and amino acid product portfolio into its production sites in Wuming, China, and Ham, France, under the unified REXIM® brand.

Part of the Hanau site involved in this sale previously supported the production of active pharmaceutical ingredients (APIs), intermediates, and pharmaceutical lipids. The GMP facility for advanced pharmaceutical lipids at this site will continue operations to provide clinical and small-scale commercial production, aligning with Evonik's strategy to focus on high-growth areas.

For the ProChem Group, this acquisition brings advanced facilities, quality-assured processes, and industrial infrastructure, helping to expand its service portfolio. ProChem is a multi-site contract manufacturer covering synthesis, distillation, extraction, drying, blending, milling, sieving, packaging, and in-depth analytical testing, serving the pharmaceutical and related industries.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com